Navigation Links
Faulty proteins may prove significant in identifying new treatments for ovarian cancer
Date:1/13/2012

PORTLAND, Ore. -- A constellation of defective proteins suspected in causing a malfunction in the body's ability to repair its own DNA could be the link scientists need to prove a new class of drugs will be effective in treating a broad range of ovarian cancer patients, an Oregon Health & Science University Knight Cancer Institute study found.

These research results, published this week in PLoS ONE, have prompted additional exploration into whether the patient population included in clinical trials for drugs that target the enzyme poly ADP ribose polymerase (PARP) should be expanded. Several forms of cancer are more dependent on PARP for their growth than regular cells, which means that targeting these enzymes when they go haywire is a potentially effective way to treat ovarian cancer. Currently PARP inhibitors are being tested with patients who have two types of malfunctioning proteins, BRCA1 or BRCA2. But, the OHSU Knight Cancer Institute study of additional proteins, beyond BRCA proteins, suggests that they too are playing a role in driving ovarian cancer.

Tapping into the potential of PARP inhibitors could change the dynamics of ovarian cancer treatment. There has not been a substantial increase in treatment options for ovarian cancer in the past two decades, said Tanja Pejovic, M.D., Ph.D., gynecologic oncologist at the OHSU Knight Cancer Institute. Pejovic, who led the study of these additional defective proteins, added that the results provide evidence that further research into the role of multiple proteins is warranted.

Only about 10 to 15 percent of women with ovarian cancer have BRCA 1 or BRCA 2 mutations.

Pejovic's study of 186 patients with nonhereditary cancer found that 41 percent who had an early recurrence of the disease also had abnormal levels of the other proteins tracked. In contrast, only 19.5 percent of patients who hadn't yet had a recurrence of the disease in three years had abnormal levels of these proteins.

"If we are able to identify the proteins that differentiate these patients at risk for early recurrence, this would open up a new direction in ovarian cancer treatment," Pejovic said.
'/>"/>

Contact: Elisa Williams
willieli@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related biology news :

1. Faulty molecular switch can cause infertility or miscarriage
2. Faulty gene linked to disorders of sexual development
3. Faulty clean-up process may be key event in Huntingtons disease
4. Penn scientists pioneer new method for watching proteins fold
5. Lets do the twist: Spiral proteins are efficient gene delivery agents
6. Control by the matrix: RUB researchers decipher the role of proteins in the cell environment
7. Cellular processing of proteins found in Congolese child birthing tea now revealed
8. Targeted antibacterial proteins may offer antibiotic alternative
9. New technique enables study of challenging proteins
10. So many proteins, so much promise
11. Exercise before and during early pregnancy increases two beneficial proteins for mothers-to-be
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility ... Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski will ... Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE mark ...
(Date:12/2/2016)... -- The Multiple Myeloma Research Foundation (MMRF) today announced that ... —the largest and most comprehensive study driving new genomic ... presented at the 58 th American Society of ... San Diego from December 3-6. The new ... as identify pathways and targets for new drug development. ...
(Date:12/2/2016)... 2016 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced the appointment of Earl Warren ... and private healthcare investor, to its Board of Directors. ... clinical and strategic experience at the highest level," said ... "As one of the world,s leading orthopedic surgeons, Dr. ...
(Date:12/2/2016)... Diego, CA (PRWEB) , ... December 01, 2016 , ... ... data from its Phase I/II clinical trials for AC0010 at the World Conference on ... forward to providing an update on the phase I/II clinical trials for AC0010 in ...
Breaking Biology Technology: